@article{b7356154e83a4eecb4917faec23fa60e,
title = "Methotrexate in psoriasis and psoriatic arthritis",
abstract = "Methotrexate (MTX) is the most commonly prescribed first-line therapy in psoriatic arthritis (PsA) internationally and is also commonly used in the treatment of psoriasis. However, data supporting its use in PsA are limited and significant toxicities can occur. This article summarizes a debate at the 2019 Group for Research and Assessment of Psoriasis and Psoriatic Arthritis (GRAPPA) annual meeting that focused on the use of MTX in psoriasis and PsA. Four clinicians and 1 patient research partner presented clinical study data and the patient experience summarizing the efficacy, tolerability, and toxicity of MTX for both skin and musculoskeletal manifestations. A survey of attending GRAPPA members collected data on current and planned future use of MTX across the world.",
keywords = "Grappa, Methotrexate, Patient research partners, Psoriasis, Psoriatic arthritis",
author = "Coates, {Laura C.} and Merola, {Joseph F.} and Grieb, {Suzanne M.} and Mease, {Philip J.} and Duffin, {Kristina Callis}",
note = "Funding Information: From the Department of Orthopaedics, Rheumatology, and Musculoskeletal Sciences, University of Oxford, Oxford, UK; Department of Dermatology and Medicine, Division of Rheumatology, Harvard Medical School, Brigham and Women{\textquoteright}s Hospital, Boston, Massachusetts; Department of Pediatrics, Research Associate, Johns Hopkins University School of Medicine, Baltimore, Maryland; Rheumatology Research, Swedish Medical Center/Providence St. Joseph Health and University of Washington School of Medicine, Seattle, Washington; Department of Dermatology, University of Utah, Salt Lake City, Utah, USA. As part of the supplement series GRAPPA 2019, this report was reviewed internally and approved by the Guest Editors for integrity, accuracy, and consistency with scientific and ethical standards. L.C. Coates is funded by a National Institute for Health Research (NIHR) Clinician Scientist award. The research was supported by the NIHR Oxford Biomedical Research Centre. The views expressed are those of the authors and not necessarily those of the UK National Health Service (NHS), the NIHR, or the Department of Health. L.C. Coates, MB ChB, PhD, Department of Orthopaedics, Rheumatology, and Musculoskeletal Sciences, University of Oxford; J.F. Merola, MD, MMSc, Department of Dermatology and Medicine, Division of Rheumatology, Harvard Medical School, Brigham and Women{\textquoteright}s Hospital; S.M. Grieb, PhD, MSPH, Department of Pediatrics, Research Associate, Johns Hopkins University School of Medicine; P.J. Mease, MD, Rheumatology Research, Swedish Medical Center/Providence St. Joseph Health and University of Washington School of Medicine; K. Callis Duffin, MD, MS, Associate Professor and Co-Chair, Department of Dermatology, University of Utah, and President, GRAPPA. Address correspondence to L.C. Coates, Department of Orthopaedics, Rheumatology, and Musculoskeletal Sciences, University of Oxford, Botnar Research Centre, Windmill Road, Oxford, UK. E-mail: laura.coates@ndorms.ox.ac.uk Publisher Copyright: {\textcopyright} 2020 Journal of Rheumatology. All rights reserved.",
year = "2020",
month = jun,
day = "1",
doi = "10.3899/jrheum.200124",
language = "English (US)",
volume = "96",
pages = "31--35",
journal = "Journal of Rheumatology",
issn = "0315-162X",
publisher = "Journal of Rheumatology",
}